Hormonal
Akkermansia muciniphila supplementation in obese humans leads to greater weight loss and decreased plasma LPS levels compared to placebo, suggesting a direct microbiome-based therapy for obesity.
Akkermansia muciniphila is a specific gut bacterium that has shown promise in clinical trials for aiding weight loss in obese individuals. While not yet a formal recommendation, consuming foods that support this bacterium (like polyphenols) may be beneficial. Consult a healthcare provider before considering specific supplementation.
Obese patients who received A. muciniphila supplementation achieved more weight loss compared to those who received placebo, and metabolic changes in the treatment group were associated with decrease in plasma LPS levels.
Why this rating
Cited as a 'recent clinical trial' in humans, though the paper notes 'mixed' outcomes for probiotics in general.
Source
Leveraging the Microbiome for Obesity: Moving From Form to Function
Anna H. Lee et al. · Frontiers in Endocrinology · 2022
DOI 10.3389/fendo.2022.918923
More from this paper
- Gut microbiome-derived short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate exert anti-obesity effects by activating G protein-coupled receptors (GPR43/GPR41) and inhibiting histone deacetylase (HDAC), which stimulates the release of satiety hormones (GLP-1, PYY) and increases energy expenditure.Moderate
- Bile acids, specifically secondary bile acids like ursodeoxycholate (UDCA) and lithocholate (LCA), and the activation of the TGR5 receptor, contribute to metabolic improvements and weight loss by stimulating GLP-1 release and increasing adipose tissue thermogenesis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →